Stay updated with breaking news from Nasdaq Ortx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities analysts expect Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) to report earnings per share of ($0.25) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Orchard Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.22). Orchard Therapeutics posted earnings […]
Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) CEO Bobby Gaspar bought 15,000 shares of the firm’s stock in a transaction that occurred on Friday, April 1st. The shares were purchased at an average cost of $0.74 per share, for a total transaction of $11,100.00. The transaction was disclosed in a legal filing with the SEC, […]
Sumitomo Mitsui Financial Group reaffirmed their neutral rating on shares of Orchard Therapeutics (NASDAQ:ORTX – Get Rating) in a report published on Friday morning, Marketbeat reports. Several other brokerages also recently commented on ORTX. Cantor Fitzgerald assumed coverage on Orchard Therapeutics in a research note on Thursday, December 30th. They issued an overweight rating and […]
Cowen cut shares of Orchard Therapeutics (NASDAQ:ORTX – Get Rating) from an outperform rating to a market perform rating in a research note issued to investors on Thursday, The Fly reports. A number of other equities analysts have also recently weighed in on the company. Stifel Nicolaus reiterated a buy rating on shares of Orchard […]
First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated...